KOL Views: How much room is there for a fourth ALK inhibitor in NSCLC, and how might Takeda’s Alunbrig differentiate itself?

The driving force behind Takeda’s $5.2-billion acquisition of Ariad Pharmaceuticals earlier this year is believed to be Alunbrig (brigatinib), which last week secured approval in the US for second-line treatment of ALK-positive non-small-cell lung cancer (NSCLC). But with three other ALK inhibitors already on the market, the Japanese pharma’s task now is to prise market share away from its more established rivals. (See ViewPoints: Takeda ticks one box justifying Ariad deal, but can Alunbrig compete with Alecensa?)

To provide FirstWord readers with a better understanding of how the competition among ALK inhibitors is likely to shape up, we are hosting an expert call with a key opinion leader later this week.

Key topics that will be discussed during the call include, among other things… how do the profiles of Pfizer’s Xalkori (crizotinib), Roche’s Alecensa (alectinib), Novartis' Zykadia (ceritinib) and Alunbrig – the four marketed ALK inhibitors – stack up; how is Alunbrig likely to be used initially; what does Takeda need to do to increase uptake in the second-and third-line settings; thoughts on Alunbrig’s potential utility in the front-line setting, and what will Takeda need to demonstrate in the ongoing Phase III ALTA trial in order to win significant market share; and how much of a threat is Pfizer’s next-generation lorlatinib?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment landscape for ALK inhibitors.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.